Employers Dropping GLP-1 Coverage: 2026–2027 Data

Weight Loss Provider Guide Research is an independent research and reference resource covering access, coverage, and policy for medical weight-management care.

The finding

Employers dropping GLP-1 coverage are a real but still minority part of the market. The larger shift is toward keeping weight-management coverage while making it harder or more expensive to use.

Mercer's 2026 survey found that 6% of large employers dropped weight-loss GLP-1 coverage in 2026, another 5% planned to drop it for 2027 or were actively considering doing so, and 27% tightened utilization controls in 2026 or planned to in 2027. Mercer surveyed 604 U.S. organizations from April 15 through May 8, 2026, including 481 organizations with at least 500 employees. Source: Mercer

We then looked for the employers themselves. The Employer GLP-1 Coverage Action Tracker contains 15 unique employer actions represented by 16 plan-level records. Eight actions ended weight-management coverage, five retained coverage with tighter eligibility, program, formulary, duration, or member-cost rules, and two maintained or expanded access through a managed pathway.

In all eight documented exclusions, the employer or plan sponsor said coverage for type 2 diabetes would continue. That does not mean every diabetes prescription is automatically covered. It means the published action was an exclusion of the weight-management indication, not a removal of every GLP-1 benefit.

The tracker is a public-document convenience sample. It is not a national prevalence estimate. Universities, public employers, and benefit trusts publish detailed plan materials more often than private companies, so they are overrepresented.

Quick reference

Sources: Mercer, Survey on Health and Benefit Strategies for 2027; Business Group on Health 2026 GLP-1 survey; Weight Loss Provider Guide Research, Employer GLP-1 Coverage Action Tracker v1.0. Tracker figures describe only the 15 documented actions in this dataset.

How many employers are dropping GLP-1 coverage?

The clearest completed-action estimate is Mercer's finding that 6% of large employers dropped weight-loss GLP-1 coverage in 2026. Forward-looking surveys show that some current coverers expect to stop in 2027, but those figures use different samples and denominators and should not be merged into one number.

What the national employer surveys found

Sources: Mercer; Business Group on Health; KFF; WTW; IFEBP.

Why the coverage estimates range from 19% to 67%

The range is mostly a sample-design problem, not proof that one survey is wrong.

Employer size changes the answer. KFF found 16% coverage at firms with 200–999 workers, 30% at firms with 1,000–4,999 workers, and 43% at firms with at least 5,000 workers. Business Group on Health surveys its own mostly very large employer membership. A survey concentrated at the top of the size distribution should produce a higher coverage rate than a random employer survey.

The questions are not identical. KFF asks whether the firm's largest plan covers GLP-1 agonists when used primarily for weight loss. IFEBP reports the share covering the drugs for both diabetes and weight loss. Mercer and Business Group on Health ask more directly about weight-loss or weight-management coverage.

The field periods are different. KFF's figures describe 2025. Mercer and Business Group on Health collected data in spring 2026. Plan changes can take effect between those measurements.

Three arithmetic errors to avoid

Do not average the survey percentages. A mean of 19%, 36%, 49%, and 67% would describe no real employer population.

Do not add Mercer's 6% and 5% and call it an 11% 2026 drop rate. The 6% is a completed 2026 action. The 5% is a 2027 plan or active consideration. They describe different years and different decision states.

Do not divide Mercer's 5% by its 49% coverage figure to manufacture a common denominator. Mercer describes 49% as the share that covered the benefit “last year,” while the 5% concerns 2027 intentions. The release does not establish that those figures can be divided.

The clean national conclusion is narrower and stronger: some employers are dropping coverage, more are tightening it, and coverage remains far more common among the largest employers.

Employers dropping GLP-1 coverage: which plans ended the benefit?

This tracker identifies 15 unique, publicly documented employer actions from 2023 through July 2026. Eight ended weight-management coverage, five kept coverage under tighter rules or higher member costs, and two maintained or expanded managed access.

The table contains 16 plan-level records because the University of Texas System applied one decision to UT SELECT and UT CARE on different effective dates. The summary counts that as one employer action.

Employer GLP-1 Coverage Action Tracker, version 1.0

Source: Weight Loss Provider Guide Research, Employer GLP-1 Coverage Action Tracker v1.0. Every record is based on a public employer- or plan-sponsor document and was last verified July 31, 2026.

↓ Download the complete tracker data as CSV

What the tracker owns that the individual sources do not

No single employer document can establish a market pattern. The original value here is the normalized structure across all records:

• one action ID for one employer decision, even when multiple plan records exist;
• separate fields for weight-management, diabetes, and other indications;
• separate treatment of existing users, grandfathering, transition funding, program requirements, clinical criteria, formulary changes, and member cost;
• a source tier and last-verification date for every record;
• a classification that keeps exclusions separate from restrictions and managed continuation.

That distinction matters because a headline saying an employer “dropped GLP-1 coverage” can describe very different events.

What does “dropping GLP-1 coverage” actually mean?

The phrase covers several different benefit actions. Only a full exclusion means the plan has stopped paying for weight-management treatment for the affected population.

Ten distinct coverage actions found in employer documents

Source: Weight Loss Provider Guide Research classification of the public employer-plan documents linked in the Employer GLP-1 Coverage Action Tracker v1.0.

This taxonomy is intentionally stricter than ordinary news language. A plan that adds a program requirement has reduced access, but it has not done the same thing as a plan that excludes every current and future weight-management claim.

Mercer's survey reflects that distinction. Its 27% utilization-control figure is much larger than its 6% completed-exclusion figure. The dominant action in 2026 was restriction, not elimination.

Why are employers changing GLP-1 coverage now?

The public evidence points to three recurring pressures: rapid pharmacy spending growth, utilization above employer expectations, and uncertainty about when clinical benefits will produce measurable savings inside an employer's own claims data.

Those are employer and plan-sponsor rationales. They are not independent proof that coverage is or is not cost-effective.

National cost and utilization evidence

KFF found that among firms covering weight-loss GLP-1s:

• 44% of firms with 1,000–4,999 workers and 59% of firms with at least 5,000 workers said use was higher than expected.
• 43% of firms with 1,000–4,999 workers and 66% of firms with at least 5,000 workers said coverage had a “significant” effect on prescription-drug spending.
• 34% of covering firms with at least 200 workers required a dietitian, case manager, therapist, or lifestyle program as a condition of coverage.

Source: KFF 2025 Employer Health Benefits Survey

Business Group on Health found that nearly eight in ten surveyed employers said GLP-1s were increasing company health-care costs. More than half of current coverers expected meaningful clinical benefits, but few said they had yet seen evidence such as lower obesity rates or fewer bariatric surgeries in their aggregated claims. Source: Business Group on Health

IFEBP reported that weight-loss GLP-1 claims averaged 11.4% of total annual claims for corporate respondents in 2025 and 14.7% for multiemployer and public-employer respondents. Source: IFEBP

Cost figures published by individual plans

Sources: UT Benefits; North Carolina State Health Plan; HCPSS; MMHG. These are sponsor-reported figures, not independently audited estimates.

The HCPSS wording is easy to misread. The published notice does not say total cost was $3.6 million over two years. It says that over two years, the cost for a three-month period rose from $485,000 to more than $3.6 million.

Does a GLP-1 coverage drop also apply to diabetes?

Not in the eight exclusions documented here. Every one retained coverage for type 2 diabetes, although prior authorization, formulary, and diagnosis requirements can still apply.

Indication matrix for the eight exclusions

Source: Employer GLP-1 Coverage Action Tracker v1.0 and the public plan documents linked in the tracker.

The brand name can also signal the indication. Semaglutide is sold as Ozempic for type 2 diabetes and Wegovy for chronic weight management. Tirzepatide is sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. The active ingredient may be the same, but the FDA-labeled indication and the plan's coverage rules are not.

That is why “my employer stopped covering Ozempic” and “my employer stopped covering Wegovy” cannot be treated as interchangeable statements without reading the actual formulary and authorization criteria.

What happens to employees already taking a GLP-1?

There is no standard transition rule. The documents show immediate exclusions, temporary grandfathering, a funded reimbursement account, required program enrollment, reauthorization, and product substitution.

Source: Employer GLP-1 Coverage Action Tracker v1.0 and the public plan documents linked in the tracker.

The University of Minnesota notice says the KwikPen requires pen needles obtained separately at the pharmacy, but it also says the needles are covered on the formulary. The source does not support describing that detail as a new out-of-pocket cost.

If coverage is ending

This page is informational and is not medical advice.

A plan exclusion and a prior-authorization denial are different problems. A denial may have an appeal process. A category exclusion may leave no ordinary authorization pathway, although a plan can create a separate exception process. Delaware, for example, excludes Zepbound from its formulary but allows a clinical exception for eligible members.

The indication can change the answer. A person treated for type 2 diabetes or another covered diagnosis may face different rules from a coworker treated solely for weight management.

The current plan documents control. The U.S. Department of Labor describes the Summary Plan Description as the document that tells participants what the plan provides and how it operates. Check the current formulary, Summary Plan Description, amendments, and any open-enrollment notice, then confirm with the plan administrator. Source: U.S. Department of Labor

Do not stop or alter a prescription solely because of general information online. In the STEP 1 extension, participants regained about two-thirds of their prior semaglutide-related weight loss one year after treatment withdrawal. In SURMOUNT-4, participants switched from tirzepatide to placebo after a 36-week lead-in had a mean 14.0% weight increase from week 36 to week 88, while those who continued tirzepatide had a further 5.5% mean decrease. Those are results in defined clinical-trial populations, not predictions for an individual. STEP 1 extension in Diabetes, Obesity and Metabolism; SURMOUNT-4 in JAMA.

Are all employers moving away from GLP-1 coverage?

No. Most current coverers in the two 2026 large-employer surveys said they expected to maintain coverage, and the tracker includes employers that expanded or preserved access through management rather than exclusion.

Business Group on Health found that 72% of current coverers were likely to continue in 2027, while 10% were likely not to. WTW reported that 70% intended to maintain coverage, 12% were likely or very likely to discontinue, and another 18% were somewhat likely to discontinue. Those measures are not identical, but neither supports the claim that most large employers are abandoning the benefit.

The two clearest counterexamples in the tracker are:

• Mayo Clinic, which lifted its lifetime maximum for 2026 while requiring participation in a practice-led weight-management program.
• The University of Minnesota, which moved affected members to Zepbound KwikPen, transferred existing authorizations, and said there would be no coverage gap.

The market is splitting. Some employers exclude weight-management coverage. Some keep it behind more gates. Some preserve it through a managed channel.

How fast is GLP-1 use rising compared with employer coverage?

Demand is rising faster than broad employer coverage. Gallup found that current adult use of GLP-1 medications for weight loss rose from 3% in 2024 to 11% in 2026, while KFF found only a one-point increase in weight-loss coverage among firms with at least 200 workers from 2024 to 2025.

Sources: Gallup National Health and Well-Being Index, based on a web survey of 5,065 U.S. adults conducted May 28–June 5, 2026; KFF 2025 Employer Health Benefits Survey. The populations and years differ, so this table shows parallel trends rather than a direct coverage gap.

Gallup also found that 19% of current users reported taking a compounded or custom-mixed product. Among people who had switched from a brand-name product to a compounded product, cost or insurance coverage was more commonly named as the primary reason than among people who switched in the opposite direction. That result does not show how many people moved to compounded products specifically because an employer dropped coverage, so this tracker does not use it as an employee-outcome measure.

Who controls employer GLP-1 coverage?

The answer depends on whether the plan is self-funded or fully insured. The company name on the insurance card does not always identify who made the coverage decision.

HealthCare.gov defines a self-insured plan as one in which the employer takes responsibility for paying medical claims, even if it hires a third-party administrator for claims processing, networks, or enrollment. Source: HealthCare.gov

That distinction is visible in the University of Michigan record. Blue Cross Blue Shield of Michigan and Blue Care Network announced that they would stop covering weight-loss GLP-1 drugs for fully insured members in 2025, but the university said the carrier decision did not control U-M's self-funded and self-managed prescription plan. U-M kept coverage under its own criteria. Source: University of Michigan

Large self-insured employers do not have to provide the Affordable Care Act's complete essential-health-benefit package, although many do. Fully insured plans can also be subject to state requirements. Source: HealthCare.gov

For an individual employee, the practical sources are still the same: the current Summary Plan Description, drug formulary, benefit amendments, prior-authorization criteria, and plan administrator.

How this tracker was built

We identified U.S. employer-sponsored health plans, employee-benefit trusts, public-employee plans, and employer plan sponsors with a publicly documented change to GLP-1 or anti-obesity-medication coverage effective from 2023 through July 2026.

For every included action, we reviewed a public document published by the employer, plan sponsor, benefits office, trust, or governing body. The source types include plan notices, open-enrollment pages, benefit guides, plan documents, HR updates, and board materials.

Inclusion criteria

A record qualifies only when all of these conditions are met:

1. It concerns a U.S. employer-sponsored plan, employee-benefit trust, public-employee plan, or employer plan sponsor.
2. A public employer- or plan-sponsor source documents the action.
3. The source explicitly establishes a GLP-1 or anti-obesity-medication coverage change.
4. The action took effect, or was formally scheduled to take effect, from 2023 through July 2026.
5. The action can be classified using the published taxonomy.
6. The source was retrievable and rechecked on July 31, 2026.

Exclusion criteria

We exclude:

• anonymous employer examples;
• rumors or employee reports without a public plan-sponsor source;
• carrier policies not tied to a named employer-plan decision;
• Medicare, Medicaid, and individual-market policies;
• plans that never offered coverage, unless used only as background;
• general formulary pages that do not establish a dated employer action;
• proposed changes that were not formally adopted;
• secondary reporting when the underlying employer action cannot be verified in public sponsor material.

Classification rules

Ended weight-management coverage means the affected plan no longer pays for qualifying weight-management GLP-1 treatment after the effective date.

Retained coverage with tighter rules or higher member cost means coverage remains possible, but the employer added or tightened clinical criteria, duration limits, program participation, engagement requirements, formulary rules, or member cost.

Maintained or expanded managed access means the action preserved or increased access through a defined program or product pathway.

Considering an exclusion is not a completed action. Survey intentions appear in the national evidence section, not in the employer-action tracker.

Diabetes retained is recorded only when the source affirmatively says so. It is never inferred.

Employer-stated reasons are reported as sponsor statements. They are not presented as independent economic findings.

Counting rule

One employer decision counts once. UT SELECT and UT CARE appear as two plan-level records because their effective dates differ, but both share action ID A01 and count as one action in the 8–5–2 summary.

Standardized data fields

The downloadable CSV contains:

• action and plan-record IDs;
• employer, plan, employer type, and state;
• effective date and action category;
• post-change weight-management, diabetes, and other-indication status;
• existing-user treatment and grandfathering;
• transition support;
• program, clinical, formulary, and member-cost requirements;
• products named;
• employer-stated rationale;
• source title, URL, source tier, verification date, and notes.

↓ Download the Employer GLP-1 Coverage Action Tracker CSV

What this data does not show

• This is not a representative sample. Public employers, universities, and benefit trusts publish more detail than most private employers. The 8-of-15 split describes this dataset, not the national employer market.
• Public disclosure is uneven. Private-company changes may never appear in a publicly searchable plan document. The tracker undercounts such actions by an unknown amount.
• The survey estimates are not interchangeable. Mercer, KFF, Business Group on Health, WTW, and IFEBP use different samples, questions, employer-size mixes, and dates.
• Intentions are not completed actions. “Likely not to continue,” “planning to drop,” “actively considering,” and “dropped” remain separate throughout this page.
• Coverage is indication-specific. A weight-management exclusion does not automatically establish what happens for diabetes, cardiovascular disease, sleep apnea, or another diagnosis.
• An employer action can affect several plans. The tracker stores plan-level records but counts unique employer decisions in its headline totals.
• Renewal dates can scatter implementation. A change described as a 2026 plan-year change may reach groups on different renewal dates.
• Plan documents can change. The verification date records when we rechecked a source. It is not a promise that the policy will never be amended.
• The tracker measures benefit design, not employee outcomes. It does not measure treatment discontinuation, clinical outcomes, alternative purchasing, appeals, or what employees ultimately paid.

Frequently asked questions

How to cite this page

Weight Loss Provider Guide Research. “Employers Dropping GLP-1 Coverage: 2026–2027 Data and Tracker.” Last verified July 31, 2026. https://weightlossproviderguide.com/research/employers-dropping-glp-1-coverage/

Dataset: Employer GLP-1 Coverage Action Tracker, version 1.0. Distributed as CSV at /research/data/employer-glp-1-coverage-action-tracker.csv.

Produced by: WPG Research Team · How it was produced: Public employer-plan documents and original survey releases were located, read, standardized, and classified using the methodology above. Every tracker record links to its underlying source. Original calculations are limited to reproducible counts and percentages from the published tracker. · Last verified: July 31, 2026

Sources

National employer surveys

• Mercer, “Employers are shifting health care costs to employees but also leveraging new approaches to minimize impact,” June 11, 2026
• Business Group on Health, 2026 GLP-1 survey
• KFF, 2025 Employer Health Benefits Survey
• WTW, 2026 Rx Pulse Survey summary
• International Foundation of Employee Benefit Plans, GLP-1 Drugs: 2026 Pulse Survey

Population and clinical evidence

• Gallup, “In U.S., GLP-1 Usage Reaches New High,” July 7, 2026
• STEP 1 trial extension, Diabetes, Obesity and Metabolism, PubMed
• SURMOUNT-4 randomized clinical trial, JAMA

Plan documents

• University of Texas System
• North Carolina State Health Plan
• NY44 Health Benefits Plan Trust
• The Ohio State University
• State of Michigan
• Howard County Public School System
• University of New Mexico
• Mayflower Municipal Health Group
• University of Michigan
• State of Delaware
• Harvard University
• Texas A&M University System
• Boston College
• Mayo Clinic
• University of Minnesota

Plan interpretation

• HealthCare.gov, self-insured plan definition
• HealthCare.gov, Marketplace coverage and self-insured employers
• U.S. Department of Labor, Plan Information

Related research

• Medicaid GLP-1 Prior Authorization Criteria by State
• State Employee GLP-1 Coverage by State
• GLP-1 Pricing Index
• GLP-1 Affordability Index
• GLP-1 Telehealth True-Cost Audit
• All Weight Loss Provider Guide Research

Change log

• July 31, 2026 — Version 1.0: Published with 15 unique employer actions and 16 plan-level records.

Weight Loss Provider Guide Research is an independent research and reference resource covering access, coverage, and policy for medical weight-management care. This page is an editorial research resource. It is not medical, legal, or benefits advice. Coverage is controlled by the terms of the reader's specific plan. Treatment questions belong with the prescribing clinician.